DETERMINATION OF miRNA EXPRESSION FOR SELECTION OF THE NEXT LINE OF CHEMOTHERAPY IN BREAST CANCER PATIENTS
DOI:
https://doi.org/10.11603/1811-2471.2023.v.i3.13951Keywords:
microRNA (miRNA), chemotherapy, breast cancerAbstract
SUMMARY. This article presents an overview of theoretical data and own practical results of research on the use of miRNA for the choice of treatment tactics in case of recurrence of malignant tumors on the previous line of chemotherapy. The results of our own research were also analyzed and compared with data from scientific literature on the prognostic significance of miRNA molecules in malignant tumors. On the basis of clinical observation with the participation of 29 patients, it was established that the indicators of circulating microRNAs are an important prognostic marker of the effectiveness of chemotherapy.
The aim – to analyze one's own experience of using miRNA for the choice of treatment tactics for breast cancer recurrence.
Material and Methods. 29 patients with relapsed breast cancer were included in the study. To study the expression of the miRNA panel in blood serum, the method of reverse transcription polymerase chain reaction was used.
Results. the results of own research were analyzed and compared with data from scientific literature on the prognostic significance of microRNA molecules in malignant tumors. The clinical effect of therapy was evaluated by to the standards of tumor response assessment according to the RECIST 1.1 criteria with the calculation of the size of target foci. Complete response of the disease was achieved in 11 (37.9 %) patients, partial response in 13 (44.8 %) patients, and stabilization in 5 (17.3 %) cases.
Conclusions. on the basis of clinical observation with the participation of 29 patients, it was established that the indicators of circulating microRNAs are an important prognostic marker of the effectiveness of chemotherapy.
References
(2023). Rak v Ukraini, 2021-2022. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2021–2022. Morbidity, mortality, performance indicators of the oncology service]. Biuleten natsionalnoho kantser-reiestru Ukrainy – Bul. National Cancer Registry of Ukraine. Kyiv [in Ukrainian].
Lukianova, N.Iu., Borikun, T.V., Yalovenko, T.M., Zadvornyi,T.V., Malyshok, N.V., & Nosylna, O.V. (2019). Tsyrkuliuiuchi mikroRNK: perspektyvy vykorystannia dlia rannoi diahnostyky ta monitorynhu perebihu pukhlynnoho protsesu. [Circulating microRNAs: prospects of use for early diagnosis and monitoring of tumor progression]. Onkolohiia – Oncology, 21(3), 181-191 [in Ukrainian].
Al-Khanbashi, M., Caramuta, S., & Alajmi, A.M. (2016). Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment. PLoS One, 11(4).
Backes, C., Meese, E., & Keller, A. (2016). Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol. Diagnosis Ther., 20(6), 509-518.
Chekhun, V., Lukianova, N., & Borikun, T. (2017). The clinical significance of tumor miR-122,-155,-182, and-200b expression in patients with breast cancer. Science and Innovation, 13(5), 63-69.
Denis, H., Van Grembergen, O., Delatte, B., Dedeurwaerder, S., Putmans, P., Calonne, E., Rothé, F., … Deplus, R. (2016). MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol. BioSyst., 12, 404-413.
Gan, R., Yang, Y., & Yang, X. (2014). Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther., 21(7), 290-296.
Han, M., Wang, F., Gu, Y., Pei, X., Guo, G., Yu, C., Li, L., … Wang, Y. (2016). MicroRNA-21 induces breast cancer cell invasion and migration by suppress- ing smad7 via EGF and TGF-β pathways. Oncol. Rep., 35, 73-80.
Jung, J., Wagner, V., & Körner, C. (2016). MicroRNAs in therapy resistance of breast cancer. EMJ Oncol., 4(1), 103-112.
Kasinski, A.L., & Slack, F.J. (2011). MicroRNAs en route to the clinic: progress in validating and targeting micro-RNAs for cancer therapy. Nat. Rev. Cancer, 11(12), 849-864.
Kim, S.Y., Kawaguchi, T., & Yan, L. (2017). Clinical relevance of microRNA expressions in breast cancer validated using the cancer genome atlas (TCGA). Ann. Surg. Oncol., 24(10), 2943-2949.
Li, Q., Liu, M., & Ma, F. (2014). Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One, 9(8).
Larrea E., Sole C., & Manterola L. (2016). New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int. J. Mol. Sci., 17 (5), 627.
Matsuzaki J., & Takahiro O. (2017). Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int. J. Clin. Oncol., 22 (3), 413-420.
McGuire, A., Brown, J.A., & Kerin, M.J. (2015). Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev., 4, 145-155.
Sahlberg, K.K., Bottai, G., Naume, B., Burwinkel, B., Calin, G.A., Børresen-Dale, A., & Santarpia, L. (2015). A serum microRNA signature predicts tumor relapse and sur- vival in triple-negative breast cancer patients. Clin. Cancer Res., 21, 1207-1214.
Schooneveld, E., Wildiers, H., & Vergote, I. (2015). Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res., 17, 21.
Shao, B., Wang, X., & Zhang, L. (2019). Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technology in Cancer Res. Treat., 18, 1-9.
Sharma, G.N., Dave, R., & Sanadya, J. (2010). Various types and management of breast cancer: an overview. J. Adv. Pharm. Technol. Res., 1(2), 109-126.
Shimomura, A., Shiino S., Kawauchi J., Takizawa, S., Sakamoto, H., Matsuza- ki, J., Ono, M., Ochiya, T. (2016). A novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci., 107, 326-334.
Shimomura, A, Shine, S, & Kawauchi, J. (2016). MiniSY-5–4A novel combination of serum microRNAs for detecting breast cancer and predicting efficacy of treatment. Ann. Oncol., 27, 53.
Wang, H., Tan, G., & Dong, L. (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7(4).
Zhao, R., Wu, J., & Jia, W. (2011). Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie, 4(12), 675-680.
Zhou, M., Liu, Z., & Zhao, Y. (2010). MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem., 285(28), 21496-21507.
Wang, X.X., Ye, F.G., & Zhang, J. (2018). Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Management Res., 10, 4393-4400.
